<DOC>
	<DOCNO>NCT00268840</DOCNO>
	<brief_summary>The purpose study assess efficacy combination therapy gemcitabine docetaxelin patient locally advance metastatic pancreatic biliary adenocarcinoma .</brief_summary>
	<brief_title>The Efficacy Safety Gemcitabine Combination With Docetaxel Treat Pancreatic Biliary Cancer</brief_title>
	<detailed_description>Try new drug association advance cancer</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients age 18 year old Patients must sign informed consent prior study entry Patients Karnofsky performance status 50 % No prior chemotherapy Histologically cytologically confirm adenocarcinoma pancreas , locally advanced metastatic disease biliary cancer No previous radiotherapy locally advanced metastasis . Hematopoietic : WBC &gt; 3000/mm2 , Absolute neutrophile count &gt; 1500/mm2 , Hemoglobin &gt; 9g/dl , Platelet count &gt; 100 000/mm2 No intracerebral meningeal metastasis Pregnant Fertile patient must use effective contraception No serious medical condition illness would preclude study participation Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT SGPT &gt; 3.5 time upper limit normal ( ULN ) alkaline phosphatase &gt; 6 time upper limit normal ( ULN ) More 30 day since prior investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Pancreas biliary cancer</keyword>
</DOC>